Premature Birth. Premature/Birth NEC
Conditions
Interventions
Intervention 1: Intervention group: This group will receive 200 mg of vaginal progesterone suppositories (Abo Raihan Pharmaceutical Company, Tehran, Iran) daily. Intervention 2: Control group: The sec
Sponsors
Ardabil University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Non smoking women Single pregnancy Gestational age 28-34 weeks Age:18-37 years
Exclusion criteria
Exclusion criteria: Presence of active vaginal bleeding or definite signs of placental abruption (premature separation of the placenta) History of sensitivity or allergic reaction to progesterone or ingredients of the study drugs (suppositories or ampoules)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevention of premature birth. Timepoint: In the progesterone suppository group, women received it daily from weeks 28 to 34 of pregnancy until week 37 of pregnancy. In the proluton ampoule group, women received it weekly from weeks 28 to 34 of pregnancy until week 37 of pregnancy. Method of measurement: By taking a medical history and examination and recording the information in a checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShervin Tabrizian
Ardabil University of Medical Sciences
Outcome results
None listed